TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07900165: A Trial of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Participants With Metastatic Colorectal Cancer

Sponsor: CytomX Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 368 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07900165 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07900165 Rescue Dossier →